TCTR20180920008
Recruiting
Phase 2
A Comparative study of the conservative treatment versus multiple drilling and conventional surgical methods in the management of avascular necrosis of femoral head
Faculty of Medicine,Tabriz university Of Medical sciences,Tabriz,Iran.0 sites104 target enrollmentSeptember 20, 2018
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- multiple drilling,
- Sponsor
- Faculty of Medicine,Tabriz university Of Medical sciences,Tabriz,Iran.
- Enrollment
- 104
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •all patients with ONFH
Exclusion Criteria
- •exclusion criteria was patients with ONFH caused by trauma and Ficat stage of III and IV
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Treatment of Tennis Elbowateral Epicondylitis.Lateral epicondylitisIRCT2015110224596N2Vice Chancellor for Research of the Hamadan University of Medical Sciences30
Completed
Phase 3
Study of four conservative treatment of osteoarthritisOsteoarthritis.IRCT20190114042360N1Hamedan University of Medical Sciences120
Recruiting
Phase 4
Evaluation of two different conservative treatment concepts for non-dislocated radial head fracturesDRKS00024018Evangelisches Krankenhaus Oldenburg40
Recruiting
Not Applicable
Investigation and comparison of two treatment protocols based on transcranial direct current stimulation (Tdcs) and treatment based on acceptance and commitment (ACT) on reducing the intensity of pain, anxiety and depression in patients with rheumatoid arthritis.rheumatoid arthritis.IRCT20240629062274N1Khoram-Abad University of Medical Sciences60
Active, not recruiting
Phase 1
A randomized study comparing maintenance therapy withsubcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system, or other not further classified low malignant lymphoma by immunohistochemistry.MedDRA version: 14.1Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-023407-95-ITROCHE692